Purpose Patient-reported outcomes (PROs) provide the patient's perspective of the impact of treatment. Evidence suggests that PRO content of randomised controlled trials (RCTs) protocols is generally sub-optimal. This study aimed to describe and evaluate the PRO-specific content of ovarian cancer RCT protocols. Methods Published, phase III, ovarian cancer RCTs with PRO endpoints were identified following a systematic search of Medline and Cochrane databases (Jan 2000 to Feb 2016). Corresponding RCT protocols were downloaded (if published) or obtained by contacting authors. Two investigators independently assessed adherence of PRO-specific content of included protocols to a checklist of 58 recommended PRO protocol items currently being developed by the International Society for Quality of Life
Introduction
Quality of life (QOL) and other patient-reported outcomes (PROs) are important endpoints in ovarian cancer randomised controlled trials (RCTs), as the disease and its treatment can result in significant morbidities [1] . PROs are particularly important in patients with recurrent ovarian cancer where survival time is relatively short [1] . The average 5-year survival rate for ovarian cancer is approximately 44-46 %, and there has been very little Electronic supplementary material The online version of this article (doi:10.1007/s11136-016-1339-x) contains supplementary material, which is available to authorized users. improvement in survival over the past 30 years [2, 3] . PRO data are therefore crucial in evaluating the effectiveness or superiority of a therapeutic intervention, determining whether the treatment improves cancer-related symptoms or has acceptable toxicity as assessed by patients [4] . Accordingly, PROs have been included as secondary endpoints in ovarian cancer RCTs for many years [5] . However, the methodological quality of these PRO studies has, to our knowledge, never been scrutinised.
A comprehensive, high-quality protocol is critical in ensuring rigorous methodology for all RCT endpoints, including PROs [6, 7] . The protocol is a key document for communicating the research rationale, standardised methodology, and ethical considerations to trial investigators and data collection staff [6] . For this reason, the quality of trial protocols is closely scrutinised by trial sponsors, ethics committees and increasingly by the broader research community when made accessible through publication or trial registration [8] . Given that RCTs are unlikely to be replicated, it is crucial that PRO studies are carefully planned and that these plans are clearly and comprehensively described in the protocol, to yield meaningful and high-quality PRO research evidence [7] .
It is of concern, therefore, that a recent review of PRO content of trial protocols in the UK found that on average, only one-third of recommended PRO protocol content was addressed [9] . This study sample included RCTs from a range of health disciplines, but only four from oncology. The main objective of the present study was to describe and evaluate the PRO-specific content of ovarian cancer RCT protocols against a checklist of recommended protocol items for PRO endpoints in RCTs.
Methods

Identification of RCTs
Published, Phase III, ovarian cancer RCTs of biomedical interventions with PRO endpoints were identified using three methods: (1) a systematic search of Medline and Cochrane Clinical Trials databases from 1 January 2000 to 1 February 2016 for relevant publications (see ESM of Appendix 1 for the full search strategy, which was developed with assistance from a librarian); (2) searching reference lists of included papers for additional, relevant RCTs; and (3) contacting the Gynaecologic Cancer InterGroup (GCIG) Symptom Benefit Working Group (SBWG) to identify any additional published RCTs.
In order to maintain a focus on high-quality biomedical ovarian cancer RCTs for which PRO evidence may impact clinical practice, we excluded RCTs of mixed cancer samples (i.e. ovarian ? other cancer types), samples of \50 patients, and complementary, alternative, and psychological interventions. We also excluded non-English publications to avoid potential translation bias. We restricted to published RCTs, rather than searching trial registries for eligible trials, as these protocols will be included in a separate subsequent analysis involving both the publication and protocol of each RCT.
RCT protocols were downloaded from the journal's website when published as an appendix to the RCT manuscript or obtained by contacting (by email) corresponding authors of the RCT publications. Failure to respond to two emails, sent up to 6 months apart, was considered non-response. We were able to identify alternative email addresses for some corresponding authors via clinical networks after the contact email noted on the RCT publication had bounced. RCT authors were assured that protocols would be deidentified in analyses and publications to encourage participation, and for the benefit of education and quality improvement of future protocols. This was intended to minimise risk of original protocols being 'improved' for evaluation. RCT authors were not provided with a copy of the PRO protocol checklist used for the same reason.
Protocol evaluation
Two authors (RMB, PK) independently reviewed the PROspecific content of protocols against a checklist of recommended PRO protocol items (ESM of Appendix 2). The draft checklist content was derived from a previous systematic review [10] and is currently being refined by the International Society for Quality of Life Research (ISOQOL) Taskforce for Best Practices for PROs. Ultimately, the ISOQOL Taskforce aims to develop a PRO-specific extension to the SPIRIT 2013 Statement (Standardised Protocol Items for Randomised Trials) [6, 7, 11] . The PRO protocol checklist includes 58 items: 56 relating to PRO-specific content of the main protocol (e.g. rationale for including PROs, assessment time points, PRO measures, planned analyses); and two general items (identification of PRO sections of the protocol in table of contents and provision of references for key PRO statements). Item P17 of the checklist (sample size for the PRO study) is directed only to RCTs with a primary PRO endpoint; however, we assessed all protocols for this item regardless of PRO endpoint status, as we noticed early on (and wanted to document) that many of the protocols with secondary PRO endpoints had addressed PRO sample size.
The checklist also includes six items related to the PROspecific content of protocol appendices. For each included protocol, a score of 1 was allocated to each PRO checklist item completely addressed, 0.5 to items partially addressed, 0 to items not addressed, and 'not applicable' (N/A) was recorded when appropriate. A total score for the main sections of each protocol (i.e. excluding the appendices) was calculated and converted to a percentage using a denominator of 58 minus the number of 'N/A' items, if any. Protocol appendices were analysed separately, as an appendix was not evaluable for all RCTs.
Inter-rater agreement was calculated using Cohen's kappa statistic. Scoring was compared at regular intervals to ensure consistent and accurate interpretation of checklist items. Some checklist items required discussion to clarify meaning, including Item P17 (as described above); Item P9 (we accepted statements identifying PROs as a secondary endpoint, regardless of whether or not PROs were identified as a 'key' secondary endpoint); and P45 (we interpreted 'response rates' in this context as the proportion of returned questionnaires required for valid analysis, rather than clinical response rate or change in PRO scores). Scoring discrepancies were resolved through discussion with a senior investigator (MK, MC, or MF). We tested the null hypothesis that PRO protocol checklist scores would not improve over time by calculating Spearman correlation using a pre-specified alpha level of 0.05. We also ran a series of exploratory t tests (post hoc) to determine whether there were differences in mean protocol checklist score for international studies (Y/N), commercial sponsorship (Y/N) and trials group sponsorship (Y/N), using a Bonferroni adjusted alpha of p = 0.017. All analyses were conducted using SPSS (version 22, Armonk, NY: IBM Corp). Figure 1 summarises the RCT selection process. Of 41 eligible trials identified, 26 protocols were assessed (8 published, 18 provided by authors). The remaining 15 could not be obtained (9 non-response, 4 email bounces, 1 refusal, and for 1 a report was sent to us rather than the protocol). Interrater agreement was excellent (j = .87, p \ 0.001).
Results
Characteristics of 26 included protocols
Characteristics of 26 included protocols are included in Table 1 . Protocols were developed between 1995 and 2010. Year of development was not stated for two protocols. Eleven protocols were for international RCTs (national RCTs n = 7, unclear n = 4). Twenty-four had a secondary PRO endpoint; one RCT had a co-primary PRO endpoint [with progression-free survival (PFS)]; and the status of the PRO endpoint in one RCT was unclear. The majority of RCTs had a primary endpoint of PFS (n = 16) and were of chemotherapy (n = 21). The most commonly used PRO measure was the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30, n = 19) and ovarian cancer module (QLQ-OV28) (n = 11).
PRO protocol checklist items not relevant and excluded
Two PRO protocol checklist items were not relevant to any protocols in the sample and were rated N/A: none of the protocols included a validation study for PRO measures (Item P21) or permitted proxy assessment (P26). Only five protocols administered PROs to a sub-sample; therefore, the item requesting justification of sampling method (P6) was only applicable to these five protocols. The item describing order of administration of multiple PRO measures (P29) was not applicable to the 19 trials that used EORTC measures (where the administration order is standardised: QLQ-C30 then QLQ-OV28), or only one PRO measure. Twelve protocols each had three N/A items, and the remaining 14 protocols had four N/A items. This reduced the highest possible PRO protocol checklist total score (i.e. denominator) to 55 or 54, respectively.
PRO-specific content of protocols
Protocols addressed a mean of 28 % (SD 13.7 %) applicable PRO checklist items (excluding appendices), with scores ranging from 8 to 66 %. Only two protocols (developed in 2004 and 2005) addressed more than 50 % of recommended items, and 50 % of the 26 protocols scored between 20 and 40 %. PRO protocol checklist total scores are summarised in Table 2 . There was a trend towards total PRO protocol checklist scores improving overtime; however, it was not statistically significant: r = 0.37, p = 0.07 [95 % CI -0.35, 0.68] (see ESM of Appendix 3). There were no significant differences in PRO protocol checklist score for international compared to national RCTs (p = 0.93), commercial sponsorship (p = 0.14) or trials group sponsorship (p = 0.28).
The PRO-specific content of included protocols, including the number of protocols addressing each checklist item in full or partially, is graphed by order of adherence frequency in Fig. 2 . Briefly, 15 protocols (58 % of the assessed protocols) provided a rationale for assessing PROs, but only eight (31 %) described a PRO objective. Twenty-four (92 %) included a PRO assessment schedule, but only six (23 %) justified timing and 6 provided acceptable assessment windows. Twelve protocols (46 %) provided staff data collection instructions, and six encouraged staff discussion with patients of the importance of PRO assessments. Only four (15 %) included plans for monitoring PRO compliance. Sixteen (62 %) included some form of PRO analysis plan, but only nine (35 %) stated how missing data would be described and two (8 %) included plans for controlling for multiplicity.
Protocol appendices
Five protocols (19 %) included a sample of the patient information sheet, which addressed the PRO study, four (15 %) included a standardised form for collecting reasons for missing PRO data, 16 (62 %) included a copy of the PRO measure being used, and five (19 %) included evidence of permission to use the measure.
Discussion
Summary of findings
This study evaluates the PRO-specific content of ovarian cancer trial protocols, a patient cohort for which PROs have long been considered important endpoints in comparative effectiveness research. On average, protocols addressed less than one-third of recommended PRO checklist items. This low total score suggests that, on average, some potentially important PRO guidance is missing from protocols.
It is concerning that only 31 % of protocols included a clear PRO objective, 19 % included a PRO-specific hypothesis, 23 % justified timing of assessment, and 58 % justified the PRO measure used. These are crucial to good PRO study design; they require thoughtful planning to reliably capture treatment effects and enable meaningful comparisons between treatment arms, and accordingly, need to be addressed in the protocol. If the PRO measure used is not sensitive to treatment toxicities, or if the timing of assessment is not scheduled to capture relevant toxicities, any real differences between groups or clinically important treatment effects may not be understood by the PRO assessment. Ultimately, PRO design decisions impact what treatments are approved for use and offered to patients; therefore, the methodology must be carefully justified in the protocol. Regulatory bodies, such as the Food and Drug Administration (FDA) and European Medical Association (EMA), recognise the value and importance of high-quality PRO assessment in the therapeutic approval process and accordingly offer PRO assessment guidance [12] [13] [14] . Likewise, the Cochrane handbook offers clear guidelines for assessing the PRO evidence of intervention research in the context of conducting a systematic review [15] . We note that these guidelines (although targeted to trial publications) marry with the PRO protocol checklist used in the present study, demonstrating that trial design considerations relevant to the protocol are also relevant to publications.
Whilst the majority of protocols included basic PRO information, such as identifying the PRO as a primary or secondary endpoint (92 %), specifying the assessment schedule (96 %), and describing the PRO measure (85 %), other key details required for standardising PRO methodology were often not addressed. For example, 54 % stated whether baseline PRO assessment should occur before randomisation, only 27 % provided acceptable PRO assessment time windows, and 46 % stated where questionnaires should be completed. PRO assessments taken a day before administration of chemotherapy are likely to differ from those taken a day or a week after chemotherapy due to differences in toxicity, and whether or not the targeted days are captured by the questionnaire's recall period [16] . Additionally, if baseline PRO assessment occurs after the intervention has commenced, the assessment may be invalid if the intervention impacts PRO scores. Some experts also recommend standardisation of assessment timing relative to the patient's appointment with their clinician, so that news of disease status does not impact PRO scores, yet only 54 % of protocols addressed this. Our findings are concerning because lack of clear protocol guidance could lead to variation in PRO measurement practice, which may increase variability in the PRO data and potentially lead to bias [7, 17] . Central PRO compliance monitoring is a useful strategy for identifying potential issues in real time, to enable timely intervention and to avoid persistent problems, yet only 12 % of protocols described PRO-specific monitoring procedures.
Recent evidence suggests that data collection staff often finds PRO guidance inadequate [17] . Few protocols addressed staff training (8 %), specified who should administer PROs (42 %) or included guidance for discussing PRO assessments with patients (35 %). Failure to address these points in the protocol does not necessarily imply failure to educate staff or patients within the trial, but possibly suggests that education was not standardised, and may in some cases have been insufficient [17] . A recent review of strategies to minimise avoidable missing PRO data highlighted the importance of educating staff and patients about the importance of PROs [18] ; thus, staff and patient education about PROs is an important quality assurance concern. Only two protocols (8 %) noted PRO data would not inform patient care, and no protocols included a 'PRO alerts' strategy for consistent management of concerning PRO data requiring an immediate response, such as psycho-social referral for high anxiety scores [19] . Without clear guidance, staff may use their own judgment, which is likely to differ between individuals, to determine whether they examine PRO data for concerning scores, and whether and how they act on that data [20] . This may lead to cointervention bias if their intervention impacts future PROs scores [20] .
The present cohort of protocols was older (developed 1995-2010) than the protocols studied by Kyte et al. (2012 [9] ; the checklists differed slightly, as did the disease focus (the present study focuses on ovarian cancer protocols; Kyte's study included trials (any disease) funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme). Although average protocol completeness scores were similar (marginally higher in Kyte's study: 33 % compared to 28 %), there were some key differences in findings between reviews. For example, only 8 % of the HTA protocols (compared to 58 % of the ovarian cancer protocols) included a rationale for PRO assessment; 45 % of the HTA cohort included PRO-specific eligibility criteria compared to only 8 % of the ovarian cohort, and approximately 11 % of HTA (compared to zero ovarian cancer) protocols addressed management of PRO alerts [9] . It is unclear exactly what factors contributed to differences in protocol content between the two cohorts. However, it is worth noting that the systematic review that sourced PRO protocol checklist content included a large proportion of guidance sourced from oncology [10] , possibly suggesting that PRO-specific guidance differs between medical specialisations. Alternatively, differences may reflect the changing nature of PRO assessment overtime.
We anticipated that more recent ovarian cancer RCT protocols would score higher than older protocols due to an increased need for specific details. For instance, in older trials, it is likely that only paper-based PRO assessment was possible; therefore, there was little need to state mode of administration in the protocol until recently, with increased use of electronic PRO assessment. Technological advances have enabled real-time scoring of PRO data, allowing PRO data summaries to inform care in previously infeasible ways, for example by making automated PRO alerts possible. Our findings suggest that protocol completeness slightly improved with time; however, the finding was not statistically significant. The trend we observed towards higher scores overtime was likely a result of the two highest-scoring protocols being developed in 2004 and 2005.
We did not see any differences in PRO protocol checklist score for type of sponsorship or whether the trial was international or national. We did not have sufficient study power to explore the impact of these variables in a multivariate model, yet there may be some interplay between these variables. Therefore, this may be an interesting direction for future research with a larger sample size.
Our findings reinforce the need for clear, PRO-specific protocol guidance to standardise PRO methodology, improve PRO data quality and minimise the potential for bias. The modern push to publish trial protocols may persuade investigators to seek guidance for protocol development and planning of PRO studies. Publication also limits opportunity for post-hoc PRO analysis plans, as readers may verify pre-specified methodologies and analyses against those published in final manuscripts [21, 22] . A recent review of British Medical Journal trial publications (September 2013-July 2014) found 22 % of prespecified outcomes were not reported and 8 % of reported trial outcomes were not pre-specified [22] . Additionally, clear protocol guidance is likely to improve methodology and minimise rates of missing PRO data [18] . Recent estimates suggest approximately 20 % of oncology RCTs that include a PRO endpoint in the protocol go on to publish PRO findings [23] thereby wasting research resources and participants' time [24] . The reasons for failing to publish PRO data may vary; however, it is likely that many PRO studies go unpublished due to high rates of missing PRO data [25] . Although not all types of missing PRO data are preventable, strategies exist to minimise the impact of missing PRO data on data quality, and many of these must be planned and included in the protocol [18] .
Strengths
The PRO protocol checklist used in this study was developed based on a comprehensive systematic review of PRO protocol guidance [10] and has undergone preliminary refinement by the ISOQOL Best Practices for PROs Taskforce. The final, internationally-endorsed PRO Protocol Checklist will be a streamlined version of the one used in this study, with refinements based on expert and stakeholder consensus. Therefore, a strong point of our study is that our results will be comparable to future studies evaluating protocol content. We calculated the percentage PRO protocol checklist score based only on applicable items for each protocol, enabling fair assessment and comparability across protocols. Two authors independently reviewed each protocol, and inter-rater agreement was excellent.
Limitations
Despite our rigorous search strategy and persistent efforts contacting authors and engaging support from the GCIG, we were unable to obtain 37 % of the 41 identified ovarian cancer trial protocols, as many trial authors were not responsive or contactable by email. This was expected, as the RCTs were published up to 16 years ago-a time when it was uncommon for protocols to be published. It is possible that protocol content of our cohort may not be representative of the overall standard of ovarian cancer protocols. The protocol checklist used is very comprehensive, and not all items are essential for all PRO endpoints; this should be taken into account when interpreting the results of the study. The final version of the PRO protocol checklist will clarify essential items, based on Delphi consensus of key, international stakeholders. We anticipate this checklist will be available in 2018. Lessons learned from this study have been logged and will feed into future development of the PRO protocol checklist via the ISO-QOL Best Practices for PROs Taskforce.
We did not assess the quality of protocol content or suitability of chosen methodology to study aims; rather, we used an objective approach and assessed whether checklist items were addressed partially or fully in protocols. We also did not collect information about whether other forms of guidance to complement the protocol, for example study coordinators' manuals or statistical analysis plans, were used. It is possible that other forms of guidance were used and these may have described some aspects of the PRO methodology in more detail, beyond the description provided in protocols.
Conclusions and next steps
PRO sections of ovarian cancer RCT protocols varied in comprehensiveness; however, on average less than onethird of recommended PRO protocol checklist items were addressed. In some cases, guidance regarding PRO administration was lacking, which may lead to inconsistent and sub-optimal PRO methodology, and consequently suboptimal PRO data quality. Our review highlights the need for comprehensive and clear PRO-specific content of RCT protocols: in particular, a need to specify and justify PRO assessment time points, PRO administration procedures, approaches to minimise and handle missing PRO data; and plans for scoring and analysing PRO data. Research into impact of PRO-specific content of the studied protocols on reporting and the rates of missing PRO data is ongoing. Clear guidance for PRO-specific content of protocols is needed in order to improve the standard of PRO endpoints in ovarian cancer trials.
